 |
|
Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis
A Retrospective Study
Kathleen R. Page, MD;
Frangiscos Sifakis, PhD;
Ruben Montes de Oca, PhD;
Wendy A. Cronin, PhD;
Meg C. Doherty, MD, PhD;
Lynn Federline, RN;
Sarah Bur, RN;
Thomas Walsh, MD;
Walter Karney, MD;
James Milman, MD;
Nancy Baruch, RN;
Akintoye Adelakun, MD;
Susan E. Dorman, MD
Arch Intern Med. 2006;166:1863-1870.
Background Treatment of latent tuberculosis infection (LTBI) is an important aspect of tuberculosis control in the United States, but the effectiveness of this strategy is compromised by poor adherence to the recommended 9-month isoniazid regimen. In this study, we compared treatment completion and clinically recognized adverse drug reactions in patients prescribed 9 months of isoniazid therapy or 4 months of rifampin therapy for LTBI.
Methods Retrospective chart review of patients who received LTBI treatment at a public health clinic.
Results A total of 770 patients were prescribed 9 months of isoniazid therapy, and 1379 patients were prescribed 4 months of rifampin therapy. The percentages of patients who completed 80% or more of their prescribed treatment were 52.6% and 71.6% in the isoniazid and rifampin groups, respectively (P<.001). In multivariate logistic regression analysis, treatment regimen was independently associated with treatment completion (adjusted odds ratio for treatment completion, 2.88 for rifampin group vs isoniazid group; 95% confidence interval, 2.27-3.66). Clinically recognized adverse reactions resulting in permanent treatment discontinuation occurred in 4.6% and 1.9% of patients in the isoniazid and rifampin groups, respectively (P<.001). Clinically recognized hepatotoxicity was more common in the isoniazid group (1.8%) than in the rifampin group (0.08%, P<.001).
Conclusions Compared with a 9-month isoniazid regimen, a 4-month rifampin regimen was associated with a higher percentage of patients completing treatment and a lower percentage of patients with clinically recognized adverse reactions. Additional studies are warranted to determine efficacy and effectiveness of rifampin therapy for LTBI.
Author Affiliations: Department of Medicine, Johns Hopkins University School of Medicine (Drs Page, Doherty, and Dorman), Departments of Epidemiology (Drs Sifakis and Montes de Oca) and International Health (Dr Dorman), Johns Hopkins Bloomberg School of Public Health, and Maryland State Department of Health and Mental Hygiene (Dr Cronin and Mss Bur and Baruch), Baltimore, Md; and Prince George's County Tuberculosis Control Program, Cheverly, Md (Ms Federline and Drs Walsh, Karney, Milman, and Adelakun).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial
Menzies et al.
ANN INTERN MED 2008;149:689-697.
ABSTRACT
| FULL TEXT
Needed: New and Better Tools to Combat Latent Tuberculosis Infection
Blumberg
ANN INTERN MED 2008;149:761-763.
FULL TEXT
Treatment of latent tuberculosis with rifampicin is associated with higher completion rates
Nadig
Thorax 2007;62:167-167.
FULL TEXT
|
